IgniteData Taps Industry Vets to Tackle Clinical Trial Data Gridlock

NEW CASTLE, Del. – January 28, 2026 – In a strategic move signaling a major acceleration of its growth plans, intelligent automation firm IgniteData has appointed two seasoned clinical technology leaders to its senior leadership team. The company announced that Laura Hilty, a veteran strategist from firms like Advarra and Epic, will join as Chief Strategy Officer, while Joe Lengfellner, a renowned informatics pioneer from Memorial Sloan Kettering Cancer Center, will take the helm as Chief Product Officer.

The appointments come just months after IgniteData closed an oversubscribed $11 million Series A funding round, setting the stage for a significant push to scale its Archer platform. The convergence of fresh capital and top-tier talent underscores a pivotal moment for the company as it aims to solve one of the most persistent and costly bottlenecks in drug development: the manual transfer of data between clinical trial sites and sponsoring pharmaceutical companies.

“In digital health and clinical research, real innovation takes more than cutting-edge technology; it takes exceptional leaders with the vision, experience, and drive to put that technology to work,” said Zach Taft, CEO of IgniteData, in a recent statement. “This is a pivotal and incredibly exciting moment in IgniteData’s evolution.”

A Two-Pronged Attack on Inefficiency

The new hires bring a powerful combination of complementary expertise, representing both the strategic, site-centric view and the deep, institutional informatics perspective. Their combined experience is aimed squarely at refining IgniteData’s solution to the complex data flow problem.

Laura Hilty joins as Chief Strategy Officer with nearly two decades of experience shaping product strategy and driving growth at some of the industry's most influential technology firms, including Advarra, Forte Research Systems, and Epic. With a track record that includes launching six technology products and guiding six strategic acquisitions, Hilty is known for her deep understanding of the clinical research ecosystem and her focus on developing solutions that alleviate the burden on research sites. Her role will focus on amplifying product planning, forging strategic partnerships, and honing the company’s go-to-market strategy. Hilty is also a Principal at HealthX Ventures, a digital health-focused venture capital firm and an investor in IgniteData, indicating a long-standing alignment with the company's mission.

“For the better portion of my almost two decades in clinical research, I have been passionate about solving site / sponsor inefficiency problems in clinical trials in a way that is site-centric yet gives sponsors what they need to drive faster treatments for trials,” Hilty stated. “IgniteData epitomizes how these challenges can be solved through a deeply collaborative and comprehensive approach.”

Joining her is Joe Lengfellner as Chief Product Officer, a digital health innovator who spent over 15 years at the forefront of clinical research informatics at Memorial Sloan Kettering Cancer Center (MSK). At MSK, Lengfellner led a large team of technology professionals and was a key architect in deploying technologies to streamline clinical trials. He is widely recognized as a pioneer in developing and scaling EHR-to-EDC (Electronic Health Record to Electronic Data Capture) integration, the very problem IgniteData’s Archer platform is designed to solve. His work has focused on reducing the immense data management burden on sites, which often involves research coordinators manually sifting through patient records and re-entering data into multiple systems.

“In my career, I have seen first-hand how difficult it can be to transfer clinical data between sites and sponsors and how costly delays emerge when these processes break down,” said Lengfellner. “I am thrilled to join an organization that is uniquely positioned to help clinical research teams overcome these persistent challenges.”

The Technology Behind the Mission

At the heart of IgniteData's strategy is its Archer platform, an engine built to automate the secure, real-time transfer of clinical data. The platform targets the laborious “copy-and-paste” workflow that plagues clinical research, a process that is not only slow but also prone to human error. By creating a direct, intelligent pipeline from a hospital's EHR system to a sponsor's EDC system, Archer promises to make clinical trial data flow fast, reliably, and in a research-ready format.

What sets the platform apart, according to the company, is its use of generative AI and intelligent data mapping. This technology allows Archer to interpret and standardize data from diverse and often unstructured EHR formats, making it immediately usable for research purposes. This is a critical differentiator in an environment where vital patient information is often locked away in free-text physician notes or disparate, non-interoperable systems.

The impact of this automation is multi-faceted. For clinical research sites, it promises to free up highly skilled staff from tedious administrative tasks, allowing them to focus on patient care and complex study activities. For pharmaceutical sponsors, it means faster access to higher-quality data, enabling quicker decision-making and potentially shortening trial timelines. Lengfellner’s previous work at MSK, which included a successful collaboration with IgniteData on scaling EHR-to-EDC technology, serves as a powerful validation of this approach in one of the world's most demanding research environments.

Navigating a Competitive Landscape

IgniteData's aggressive growth strategy comes as the entire clinical trial industry undergoes a massive digital transformation. The market for clinical trial solutions is crowded with established giants like Medidata and Veeva Systems, which offer comprehensive software suites. However, IgniteData's focused strategy on perfecting the EHR-to-EDC data bridge—a notoriously difficult and specific pain point—could provide a decisive competitive advantage.

The company’s recent $11 million Series A funding round, led by FCA Venture Partners, also featured strategic investors like the Labcorp Venture Fund. The participation of Labcorp, a global leader in life sciences and clinical research, is a significant endorsement. It suggests a strong industry belief that solving the data interoperability challenge is critical and that IgniteData possesses a viable solution. This strategic backing could pave the way for deeper integration within the broader life sciences ecosystem, moving the Archer platform from a promising technology to an industry standard.

With new leadership, substantial funding, and a clear mission, IgniteData is poised to make its case to the wider industry. The company has already announced that its new leadership team will be present at the upcoming 17th Annual Scope Summit in Orlando, Florida, offering an early opportunity to outline their vision for a future where clinical data flows seamlessly, accelerating the development of life-saving treatments for patients everywhere.